Mean platelet volume is increased in hyperthyroidism

Department of Pathology, Wellington School of Medicine, Wellington Hospital, New Zealand.
American Journal of Hematology (Impact Factor: 3.48). 03/1988; 27(3):190-3. DOI: 10.1002/ajh.2830270308
Source: PubMed

ABSTRACT In 28 unselected patients with hyperthyroidism, platelet count, platelet hematocrit, mean platelet volume, and platelet distribution width were measured at the time of presentation and again when the patients were euthyroid. On return to the euthyroid state, there were highly significant falls in the mean values of the mean platelet volume (16% decline, P less than 0.001) and the platelet hematocrit (16% decline, P less than 0.001) and a slight but highly significant increase in the mean value of the platelet distribution width (2% increase, P less than 0.01). A decline in mean platelet volume was observed in 24 of 28 patients (86%); three patients showed no change. There was no significant change in the mean value of the platelet count. The observed effects of thyrotoxicosis on platelets appeared to be largely independent of the well-known effects on erythrocytes and white blood cells. An increase in mean platelet volume is a regular feature of hyperthyroidism that has not previously been described.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Arbeit mißt das mittlere Plättchenvolumen (MPV) im Citratblut dialysepflichtiger Patienten und untersucht es mittels bivariater Korrelationsanalyse und multivariater linearer Regressionsanalyse auf signifikante Assoziationen zu den weiteren, klinischen und biochemischen Parametern. Hierbei wurde festgestellt, daß das MPV bei dialysepflichtigen Patienten nicht nur ein Marker für verschiedene Dialyseparameter ist, sondern auch ein eigenständiger Risikofaktor für vaskuläre Erkrankungen wie arterieller Hypertonie und koronaren Herzerkrankungen.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Data regarding the association between red cell distribution width (RDW) values and mortality in patients with stable coronary artery disease are scarce. We aimed to investigate the link between mortality and RDW in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). We analyzed 2550 consecutive patients with stable coronary artery disease who underwent PCI between 2007 and 2011 at our institution. The patients were divided into four groups according to RDW quartiles. The association between the RDW values and the outcomes was assessed using Cox proportional regression analysis after adjusting for clinical, echocardiographic, hemodynamic and laboratory data in the whole population and in subgroups stratified by gender, presence of diabetes, anemia or heart failure. In the entire population, there was a stepwise relationship between RDW intervals and comorbidities. Patients with the highest RDW values were older and more often burdened with diabetes, heart failure and chronic kidney disease. There was an almost 4-fold increase in mortality during an average of 2.5 years of follow-up between the group of patients with RDW values lower than 13.1% (25th percentile) and the group with RDW values higher than 14.1% (75th percentile), (4.3% vs. 17.1%, p < 0.0001). After adjusting for the covariates, RDW remained significantly associated with mortality in the whole cohort (HR-1.23 [95% CI (1.13-1.35), p < 0.0001]) and in the subgroups stratified by gender, age (over and under 75 years), presence of anemia, diabetes, heart failure and chronic kidney disease. Higher RDW values correspond to higher comorbidity burdens and higher mortality. RDW is an independent predictor of mortality in patients with stable coronary artery disease.
    BMC Cardiovascular Disorders 12/2013; 13(1):113. DOI:10.1186/1471-2261-13-113 · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the concentration of epidermal growth factor (EGF) in platelets, serum and plasma obtained from 47 patients with Graves' disease, 7 with hypothyroidism and 20 healthy subjects. The platelets of the subjects were collected from platelet rich plasma and lysed by freezing and thawing. Subsequently the platelet debris was treated with Triton X-100. The EGF concentration was determined by homologous radioimmunoassay. The concentration of EGF in the platelets in 14 patients with untreated Graves' disease was significantly higher than that in the healthy controls. After treating these 14 patients with antithyroid agents, the EGF concentration in the platelets decreased to the level of the healthy controls. The EGF concentration in the platelets in the 7 untreated hypothyroid patients decreased after replacement therapy with thyroxine. The mean volume of the platelets in the 14 patients with untreated Graves' disease was significantly larger than in the control and decreased after treatment with antithyroid agents. The serum and plasma levels of EGF in the 7 untreated hypothyroid increased after replacement therapy. In conclusion, thyroid function affected the concentration of EGF in the platelets of patients with thyroid disorders.
    Endocrine Journal 03/1998; 45(1):83-8. DOI:10.1507/endocrj.45.83 · 2.02 Impact Factor